Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Garner CharlesOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Garner CharlesOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Series X Non-Voting Convertible PreferredNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2Price:--
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,000Price:--
-
Feb 28, 2024 (filed on Apr 10, 2024)Insider Name:Von Rickenbach Josef HOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Feb 28, 2024 (filed on Apr 10, 2024)Insider Name:Ambros Reinhard J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Ambros Reinhard J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Von Rickenbach Josef HOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Dec 15, 2023 (filed on Dec 18, 2023)Insider Name:Windsor James BrianOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:225Price:$3.37
-
Nov 20, 2023 (filed on Nov 21, 2023)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:5,076Price:$1.97
Filings by filing date
-
Feb 28, 2024 (filed on Apr 10, 2024)Insider Name:Von Rickenbach Josef HOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Feb 28, 2024 (filed on Apr 10, 2024)Insider Name:Ambros Reinhard J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Garner CharlesOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Garner CharlesOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Series X Non-Voting Convertible PreferredNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2Price:--
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,000Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Ambros Reinhard J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Von Rickenbach Josef HOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Dec 15, 2023 (filed on Dec 18, 2023)Insider Name:Windsor James BrianOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:225Price:$3.37
-
Nov 20, 2023 (filed on Nov 21, 2023)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:5,076Price:$1.97
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 12407 N. Mopac Expy., Suite 250 #390 AUSTIN TX 78758 |
Tel: | N/A |
Website: | https://aileronrx.com |
IR: | See website |
Key People | ||
Brian Windsor President, Chief Executive Officer, Director | Charles Garner Principal Financial Officer |
Business Overview |
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions. |
Financial Overview |
For the fiscal year ended 31 December 2023, Aileron Therapeutics Inc revenues was not reported. Net loss decreased 42% to $15.7M. Lower net loss reflects Pharmaceutical segment loss decrease of 41% to $16.3M, United States segment loss decrease of 41% to $16.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$6.02 to -$3.42. |
Employees: | 15 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $158.96M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$15.23M as of Dec 31, 2023 |
Net annual income (TTM): | -$15.73M as of Dec 31, 2023 |
Free cash flow (TTM): | -$19.81M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 16,972,512 as of Apr 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |